

# Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial



BASIL trial participants\*

## Summary

**Background** The treatment of rest pain, ulceration, and gangrene of the leg (severe limb ischaemia) remains controversial. We instigated the BASIL trial to compare the outcome of bypass surgery and balloon angioplasty in such patients.

**Methods** We randomly assigned 452 patients, who presented to 27 UK hospitals with severe limb ischaemia due to infra-inguinal, disease to receive a surgery-first (n=228) or an angioplasty-first (n=224) strategy. The primary endpoint was amputation-free survival (of that leg). Analysis was by intention to treat. The BASIL trial is registered with the National Research Register (NRR) and as an International Standard Randomised Controlled Trial, number ISRCTN45398889.

**Findings** The trial ran for 5·5 years, and follow-up finished when patients reached an endpoint (amputation of the leg above the ankle or death). Seven individuals were lost to follow-up after randomisation (three assigned angioplasty, two surgery); three were lost (one angioplasty, two surgery) during the first year of follow-up. 195 (86%) 228 patients assigned to bypass surgery and 216 (96%) 224 to balloon angioplasty underwent an attempt at their allocated intervention at a median (IQR) of 6 (3–16) and 6 (2–20) days after randomisation, respectively. At the end of follow-up, 248 (55%) patients were alive without amputation (of trial leg), 38 (8%) alive with amputation, 36 (8%) dead after amputation, and 130 (29%) dead without amputation. After 6 months, the two strategies did not differ significantly in amputation-free survival (48 vs 60 patients; unadjusted hazard ratio 1·07, 95% CI 0·72–1·6; adjusted hazard ratio 0·73, 0·49–1·07). We saw no difference in health-related quality of life between the two strategies, but for the first year the hospital costs associated with a surgery first strategy were about one third higher than those with an angiography first strategy.

**Interpretation** In patients presenting with severe limb ischaemia due to infra-inguinal disease and who are suitable for surgery and angioplasty, a bypass-surgery-first and a balloon-angioplasty-first strategy are associated with broadly similar outcomes in terms of amputation-free survival.

## Introduction

In most developed countries, the incidence of severe limb ischaemia, which is the presence of tissue loss (ulceration, gangrene) and pain at rest or at night, is estimated to be 50–100 per 100 000 every year and leads to pronounced morbidity and mortality as well as to the consumption of many health-care and social-care resources.<sup>1</sup> Ageing populations, the increasing prevalence of diabetes and its lower-limb-related complications, and the failure thus far to substantially reduce tobacco consumption, mean that despite advances in medical therapies, the numbers of patients needing lower limb revascularisation for severe limb ischaemia will probably increase in the foreseeable future.<sup>2,3</sup>

Two treatments are currently available; bypass surgery and balloon angioplasty. Those who favour surgery usually emphasise good long-term anatomical patency and clinical durability.<sup>4–6</sup> However, this preference could come at the cost of high morbidity and mortality as well as substantial resource use.<sup>7</sup> Furthermore, this durability could depend heavily on routine ultrasonography-based graft surveillance, often leading to repeated prophylactic re-interventions, and the use of good-quality veins for grafting.<sup>8,9</sup> Unfortunately, adequate vein is often unavailable and the long-term results of bypasses

constructed with prosthetic materials are much less satisfactory.<sup>4,10</sup> By contrast, proponents of balloon angioplasty point to the advantages of low procedural morbidity and mortality, reduced costs, the speed with which the procedure can be undertaken, and a shortened hospital stay.<sup>11</sup> Furthermore, supporters will claim that failed angioplasty does not jeopardise subsequent surgery and that, unlike bypass surgery, it preserves collaterals so that even if the angioplasty site occludes, symptoms might not return.<sup>11–13</sup> Apart from the limited patency of angioplasty, critics will state that only a few patients may be suitable for use of the transluminal technique, and that although a subintimal approach could increase applicability, the procedure is so technically demanding in these patients that satisfactory results might not be widely achievable.<sup>14–19</sup>

However, these differing opinions are based on little or no evidence. In previous studies<sup>6,20–24</sup> that have attempted to compare surgery and angioplasty for various degrees of lower limb ischaemia, all had one or more major methodological problems.<sup>16,18–21,25–32</sup>

The complete absence of level 1 evidence leads to controversy as to which treatment is associated with better clinical outcome and more effective use of health-care resources in patients with legs threatened by severe

Published online  
November 24, 2005  
DOI:?????

See [Comment](#)  
DOI:?????

\*Trial participants listed at end of report

Correspondence to:  
Prof Andrew W Bradbury,  
Department of Vascular Surgery,  
University of Birmingham, Heart  
of England NHS Foundation  
Trust, Birmingham B9 5SS, UK

[Andrew.Bradbury@heartofengland.nhs.uk](mailto:Andrew.Bradbury@heartofengland.nhs.uk)

limb ischaemia and who are potentially suitable for treatment.<sup>33-39</sup> Our aim in the BASIL (bypass versus angioplasty in severe ischaemia of the leg) trial was to compare the outcomes of a surgery-first strategy with an angioplasty-first strategy in patients with severe limb ischaemia.

## Methods

### Patients and procedures

The BASIL trial methods have been published elsewhere.<sup>40</sup> Briefly, consultant vascular surgeons and interventional radiologists in participating centres were asked to consider all patients who had presented to them with severe limb ischaemia, defined as rest pain or tissue loss (ulcer or gangrene) of presumed arterial aetiology for more than 2 weeks, and who on diagnostic imaging had a pattern of disease which, in their joint opinions, could equally well be treated by either infra-inguinal bypass surgery or balloon angioplasty. All patients provided written informed consent, and the study was approved by the multicentre research ethics committee for Scotland.

Recruitment began in August, 1999, and finished in June, 2004, during which time 452 patients underwent randomisation at one of 27 UK hospitals. Data were collated centrally and confidentially at the trial office. The trial manager, independent of participating centres, randomly assigned patients to receive either surgery first or angioplasty first using a one-to-one ratio in randomly sized permuted blocks. The randomisation sequences were generated by a computerised random-number generator in the University of Edinburgh Medical Statistics Unit (Edinburgh, UK) and supplied to the coordinating centre in identical, sealed envelopes. Randomisation was stratified by centre, and then into four groups by clinical presentation (rest pain only *vs* tissue loss with or without rest pain) and ankle pressure ( $\geq 50$  mm Hg *vs*  $\leq 50$  mm Hg).<sup>41,42</sup>

Centres were encouraged to undertake the allocated procedure as soon as possible after randomisation. The responsible consultant vascular surgeons and interventional radiologists were allowed to use their preferred techniques and equipment for diagnosis and treatment. With respect to imaging, more than 95% of the patients underwent diagnostic angiography before being allocated to receive either surgery or angioplasty. We obtained follow-up data prospectively by research nurses based in the main recruitment centres and allocated to other centres in the same UK region.

Details of patients recruited in Scottish centres were logged with the Information and Statistics Division (ISD) of the National Health Service in Scotland. Notification of death, interventions, and discharges from hospital to the end of the trial were provided by record linkage with Scottish Morbidity Records (SMR01) and General Registrar Office Scotland (GRO[S]) death records. We obtained similar information for patients from English centres using patients' reported information that was

checked through hospital paper records, hospital electronic information systems, and family practitioners. Additionally, this prospectively gathered information was crosschecked by review of all available (435 of 452) hospital case notes of trial patients at the end of the study.

Our primary outcome was time to amputation of the operated leg above the ankle or death from any cause, whichever occurred first (ie, amputation-free survival). Secondary outcomes were all-cause mortality, 30-day morbidity and mortality, re-interventions, health-related quality of life (HRQL), and use of hospital resources.

We audited the proportion of patients assigned into BASIL with respect to the total population of patients presenting with severe limb ischaemia, and investigated the reasons for non-interventional treatment and non-randomisation of potentially eligible patients. From October, 2001, to April, 2002 (about halfway through the recruitment period), we prospectively obtained data for all consecutive patients who presented with severe limb ischaemia, and who subsequently underwent diagnostic imaging with a view to revascularisation by either surgery or angioplasty, at one of the top six recruiting centres (by number of patients recruited). The responsible consultant vascular surgeons and interventional radiologists were asked to jointly record the reason why, in their opinion, potentially eligible patients were not suitable for revascularisation or randomisation.

An independent data monitoring committee met every 6 months during randomisation. The stopping rule was the observation of a highly significant difference in the primary endpoint between the treatment groups ( $p < 0.001$ ). The data monitoring committee made recommendations to the steering committee on whether the trial should continue and on the nature and the quality of the data being collected. No one apart from the data monitoring committee and independent statisticians who analysed and prepared the data had access to these analyses.

We measured self-reported HRQL using the EuroQoL 5-D (EQ5D)<sup>43</sup> and short form 36 (SF36).<sup>44</sup> These generic measures were recorded at baseline and at 3, 6, and 12 months after randomisation. The EQ5D responses were converted into a single weighted utility (preference based) score by use of the original time trade-off tariff set.<sup>45</sup> We combined the SF36 items into physical and mental component summary scores using recommended procedures.<sup>46</sup> For all three measures, higher scores indicate better health and wellbeing as perceived by the patient. Unadjusted differences in mean EQ5D weighted scores and SF36 component summary scores were assessed by simple linear regressions. Adjusted differences allowing for baseline scores were based on bias-corrected matching estimators.<sup>47</sup>

We obtained data for all interventions and hospital stays during follow-up. Patients' specific hospital use was measured by the duration of hospital stay as an aggregate unit of services provided in the inpatient hospital setting.

Total length of hospital stay was measured for 1 year from the date of randomisation. We estimated hospital use costs, using the Scottish system of hospital cost statistics for the average cost per inpatient day.<sup>48</sup>

### Statistical analysis

The sample size calculations proposed that 223 patients per treatment would be needed for a 90% power to detect a 15% difference in 3-year amputation-free survival at the 5% significance level. This calculation was based on the assumption that the 3-year survival value might be 50% in one group and 65% in the other.

We undertook the statistical analysis according to a predefined protocol. Kaplan-Meier methods were to be used to construct survival curves on an intention-to-treat basis, with the date of randomisation as time zero. Survival to the primary endpoint and a secondary endpoint (all-cause mortality) were compared by intention-to-treat analysis. We compared treatments by using mean survival to these two endpoints at 1 and 3 years from randomisation and mean values of hazard rates using a Cox model. The hazard rates were to be compared between treatments during the entire follow-up period, and calculated separately for those events occurring between randomisation and 6 months and those occurring after 6 months, and were to be adjusted for a predefined set of covariates. Covariate interactions with treatment were examined for three specified covariates (clinical stratification group, and diabetes and creatinine above or below the median) and also for a hazard score calculated from covariates that classified patients according to their risk of experiencing an endpoint. All cleaning and checking of the follow-up data were done without reference to the allocated treatment. After the survival curves were examined, a further post-hoc analysis was done that compared the risks of endpoints occurring between randomisation and 2 years and occurring after 2 years. The BASIL trial is registered with the National Research Register (NRR) and as an International Standard Randomised Controlled Trial, number ISRCTN45398889.

### Role of the funding source

The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for decision to submit for publication.

### Results

During the 6-month BASIL audit, 585 consecutive patients presented with severe limb ischaemia to the top six recruiting centres (which between them recruited 61% of the patients entered into the trial) and underwent diagnostic imaging, usually angiography, with a view to revascularisation by surgery or angioplasty. Of these, 129 (22%) needed supra-inguinal (aorto-iliac) intervention

and were therefore not the subject of the trial. Of the remaining 456 patients with severe limb ischaemia due to infra-inguinal disease (272 men, 184 women, median age 75 years [IQR 67–82]), 220 (48%) were treated conservatively without revascularisation and 236 (52%) underwent revascularisation. Of these 236 potentially eligible patients, 70 (29%) were regarded as suitable for randomisation into BASIL; of these, 22 (31%) refused trial entry and 48 (69%) were randomised.

In the audit, the main reason (more than one reason was given in many instances) for responsible surgeons and radiologists not revascularising or not randomly assigning the remaining 386 patients was that the leg could not be revascularised by either surgery or angioplasty in 154 (34%). Additionally, there was clinically significant comorbidity precluding surgery in 34 (7%) patients, there had been symptomatic improvement with medical therapy only in 14 (3%), patients were unable to provide informed consent in 16 (4%), and the patient's pattern of disease was technically unsuitable for angioplasty in 75 (16%) or surgery in 93 (20%).

	Balloon angioplasty first (n=224)	Bypass surgery first (n=228)
Male sex	128 (57%)	141 (62%)
Age		
<70 years	67 (30%)	80 (35%)
70–79 years	104 (46%)	89 (39%)
≥80 years	53 (24%)	59 (26%)
Right leg used as trial leg	103 (46%)	99 (43%)
Smoking status		
Never smoked	48 (21%)	41 (18%)
Current smoker	72 (32%)	91 (40%)
Ex-smoker (not smoked for more than 1 year)	104 (46%)	96 (42%)
Diabetes		
Not known to have diabetes	129 (58%)	133 (58%)
Insulin-dependent	39 (17%)	39 (17%)
Non-insulin-dependent	56 (25%)	57 (25%)
Angina	42 (19%)	41 (18%)
Previous myocardial infarction	44 (20%)	35 (15%)
Previous stroke or transient ischaemic attack	40 (18%)	57 (25%)
Previous intervention in trial leg	40 (18%)	27 (12%)
Previous intervention in other leg	36 (16%)	47 (21%)
Symptomatic arterial disease in other leg?		
No	151 (67%)	145 (64%)
Yes: intermittent claudication*	21 (9%)	24 (11%)
Yes: severe limb ischaemia	52 (23%)	59 (26%)
Pain at rest or at night only in trial leg	207 (92%)	205 (90%)
Tissue loss (ulcer or gangrene) in trial leg	169 (75%)	167 (73%)
Randomisation stratification group		
A: pain at rest and at night only; ankle pressure ≥50 mm Hg	45 (20%)	48 (21%)
B: pain at rest and at night only; ankle pressure <50 mm Hg	10 (4%)	13 (6%)
C: tissue loss with or without pain at rest and at night; ankle pressure ≥50 mm Hg	108 (48%)	114 (50%)
D: tissue loss with or without pain at rest and at night; ankle pressure <50 mm Hg	61 (27%)	53 (23%)
On a statin†	77 (34%)	75 (33%)
On drug treatment for hypertension	141 (63%)	134 (59%)
On antiplatelet drug‡	120 (54%)	141 (62%)
Creatinine concentration (μmol/L, mean [SD])	113 (62)	116 (95)

Data are number (%) unless otherwise stated. \*Pain in leg when walking but not at rest or at night, no tissue loss. †For hypercholesterolaemia. ‡In most cases, aspirin 75 mg daily.

**Table 1: Baseline characteristics of trial patients**

	During same hospital stay as first intervention		Following discharge from hospital after first intervention	
	Angioplasty (n=237)	Surgery (n=197)	Angioplasty (n=230)	Surgery (n=186)
Mortality	7	11	0	0
Morbidity				
Angina	4	4	1	2
Myocardial infarction	6	13	2	2
Stroke	1	3	2	0
Haematoma (numbers needing surgical drainage)	16 (2)	19 (9)	1 (0)	5 (0)
Wound infection	18	45	25	29
Chest infection	4	10	3	2
Urine infection	8	7	2	6
False aneurysm (numbers needing surgical repair)	0 (0)	2 (1)	0 (0)	0 (0)
Venous thromboembolism	1	0	2	0
Other	2	2	8	9
Further interventions				
Angioplasty	3	1	1	0
Surgery	21	2	13	0
Amputation of trial leg				
Above/below knee	4/5	3/3	0/1	0/0
Partial foot or toe	11	11	2	2
Graft re-exploration	0	5	0	0
Embolectomy	1	2	1	0
Thrombectomy	0	3	0	1
Wound debridement	3	6	1	1
Other (non-vascular)	0	0	0	1

Data are number of individuals. Patients could have had more than one morbidity or re-intervention event both before and after discharge, but within 30 days.

**Table 2: Mortality, morbidity, and re-interventions within 30 days after first intervention**

For the BASIL trial as a whole, 452 patients from 27 hospitals entered the trial. The assigned interventions were attempted for 195 (86%) of 228 patients assigned to surgery at a median of 6 days (IQR 3–16) and for 216 (96%) of 224 assigned to angioplasty at 6 days (2–20; no significant difference in time to attempt). The baseline characteristics of the patients in each group were similar and typical of those presenting with severe limb ischaemia (table 1). More than 40% were known to have diabetes and more than a third were current smokers. Most patients had tissue loss and a quarter had both legs affected by severe limb ischaemia. Many of the patients were elderly and most had a previous history of clinically significant cardiovascular disease. Despite this high occurrence, a third of patients were not receiving an antiplatelet drug and only a third of patients were receiving a statin. 33 patients were prescribed warfarin, with roughly equal numbers in the two groups.

Seven (2%) individuals (three assigned angioplasty, four surgery) were lost to follow-up after randomisation; but only three (one, two) were lost during the first year of follow-up. By the close of follow-up on Feb 28, 2005, more than 449 (99%) patients had been followed up at 1 year, 336 (74%) at 2 years, 216 (48%) at 3 years, 99 (22%) at 4 years, and 37 (8%) at 5 years. Follow-up finished once the patient had reached an endpoint

(amputation of trial leg above the ankle or death). At the end of follow-up, 248 (55%) patients had not reached the primary endpoint (ie, were alive with their trial leg intact), 38 (8%) were alive with their trial leg amputated, 36 (8%) had died subsequent to having their trial leg amputated, and 130 (29%) had died without amputation (with their trial leg intact).

Six patients randomly assigned to surgery and one to angioplasty died before undergoing intervention. 11 (5%) patients randomised to surgery and seven (3%) to angioplasty died within 30 days of their first intervention (non-significant difference). One patient in each randomised group crossed over and died within 30 days of the alternate procedure, so that the 30-day mortality associated with each procedure is the same, whether analysed by intention to treat or by first treatment received. 110 (56%) of 195 patients who were assigned to and underwent attempted surgery as their first procedure and 89 (41%) of 216 patients who were assigned to and underwent attempted angioplasty as their first procedure had one or more complications within 30 days of their intervention. However, of these 89 patients, 20 did not develop their complication until after they had gone on to have surgery as a second procedure after a failed angioplasty as a first procedure.

Table 2 describes the 30-day mortality, morbidity, and re-interventions after the first procedure, irrespective of the treatment to which they were initially allocated, and distinguishes events that occurred during the same hospital stay and those that occurred after discharge. Although we recorded no large difference in mortality, surgery was associated with a significantly higher rate of early morbidity (110 [57%] of 194) than angioplasty (89 [41%] of 216; difference 15.5%, 95% CI 5.8–24.8); these morbidity events being mainly infective, wound, and cardiovascular complications.

Of the 228 patients assigned to receive surgery, 195 underwent attempted surgery (figure 1). Of these patients, five underwent a successful endarterectomy and vein patch rather than a bypass. Two bypasses were abandoned; one because the surgeon judged the vessels as too calcified to construct a distal anastomosis, and one because the surgeon could not find sufficient usable vein for a conduit and did not want to use a prosthetic graft. In a further three patients, a graft was inserted and the operation completed but, in the opinion of responsible consultant surgeon undertaking the procedure, the bypass was not working at the end of the procedure. Therefore, the immediate failure rate was 3% (five of 195). Thus, 193 (85%) patients allocated to surgery underwent a completed surgical procedure as their first intervention, of which 188 were completed bypasses. Of these bypasses, 177 (94%) originated from the femoral artery and about 141 (75%) were constructed using the patient's long saphenous vein. About a third of the distal anastomoses were constructed at each of the following sites: above-knee popliteal artery, below-knee popliteal

artery, and crural arteries (anterior or posterior tibial or peroneal arteries).


Additionally, four patients who had been assigned to angioplasty underwent successful bypass surgery as their first intervention. By 12 months, 85 of 195 with attempted surgery had resulted in clinical failure defined by death, major amputation, or a return or persistence of symptoms (rest pain, tissue loss) in the trial leg or the finding of a technical problem with the graft on surveillance. Of the patients with a return of symptoms, 33 had a second intervention (angioplasty in most patients). Figure 1 details the outcomes of these patients undergoing further interventions, within 12 months of randomisation.

Of the 224 patients allocated to receive angioplasty, 216 underwent attempted angioplasty (figure 1). 43 (20%) of these individuals were judged as immediate technical failures. In ten, the vessel lumen could not be entered or the lesion could not be completely crossed with a guide wire. In 18, the lesion was crossed subintimally but the lumen could not be re-entered. Two procedures were abandoned before a guide wire had been passed across the disease because the patients could not tolerate the procedure. Two were terminated because of vessel perforation after a guide wire had been passed. One was terminated immediately because the lesion that had been described as being present on pre-operative duplex ultrasonography was found not to be present at the time of angiography. In a further ten procedures, immediate thrombosis of the angioplasty channel occurred, of which six also had distal embolisation, which could not be rectified either by thrombolysis or aspiration.

Of the 203 attempted angioplasties in which a guide-wire was passed across at least part of the lesion to be treated, 36% were transluminal, 50% were subintimal, and 14% were mixed. The superficial femoral artery was treated in 162 (80%) patients, and in 126 (62%) patients, more distal vessels also underwent angioplasty. Thus, the extent of the lesion that had been bypassed at surgery and recanalised by angioplasty was similar.

Furthermore, 21 patients allocated to surgery crossed over and underwent attempted angioplasty as their first intervention; of these, five were immediate failures. By 12 months, 109 of 216 patients given attempted angioplasty had resulted in clinical failure. Of these, 59 went on to have a second intervention, which in most instances was surgery.

After randomisation to surgery and attempted treatment, 109 (56%) of 195 patients were alive with the trial leg intact at 12 months without further intervention. This value compares with 107 (50%) of 216 patients after randomisation to angioplasty and attempted treatment. With respect to an intention-to-treat analysis, surgery was associated with a lower re-intervention rate than angioplasty (41 [18%] of 224 vs 59 [26%] of 228; difference 8%, 95% CI 0.04–15%). With analysis by the first intervention received, the difference between re-



**Figure 1: Trial profile at early (12-month) follow-up**


\*Three patients after surgery, 14 after angioplasty. †21 after surgery, nine after angioplasty. Seven after surgery, seven after angioplasty. ‡Nine after surgery, two after angioplasty. §Nine after surgery, two after angioplasty. See [Lancet Online](#) for webfigures 1 and 2, which show detailed outcomes and interventions of each strategy.

intervention after surgery and angioplasty increases (33 [17%] of 199 vs 67 [28%] of 237; 11%, 4–19%).


Figures 2 and 3 are Kaplan-Meier survival curves showing time to amputation of trial leg or death (whichever came first) and time to death from any cause. Survival to the primary endpoint (amputation-free survival) at 1 year was 68% and at 3 years was 57% for those assigned to surgery first; survival at 1 year was 71% and at 3 years was 52% for those randomised to angioplasty first. There were no significant differences in survival to either endpoint by randomised group. Table 3 shows hazard ratios (HR) comparing randomised treatments by Cox proportional hazards. None of the planned comparisons provided strong evidence of a difference between the treatments. However, up to 6 months, we saw a trend towards a higher rate of all-cause mortality with surgery relative to angioplasty; whereas after 6 months, we recorded a trend towards a reduced hazard in surgery with respect to both all-cause mortality and amputation-free survival.

A post-hoc analysis, done after examination of the survival curves, showed a significantly reduced hazard in amputation-free survival (adjusted HR 0.37 [95%





**Figure 2: Amputation-free survival after bypass surgery and balloon angioplasty**  
 Bars show 95% CIs for survival up to 1, 2, 3, and 4 years of follow-up, which were calculated from the cumulative hazards.



**Figure 3: All-cause mortality after bypass surgery and balloon angioplasty**  
 Bars show 95% CIs for survival up to 1, 2, 3, and 4 years of follow-up, which were calculated from the cumulative hazards.

CI 0.17–0.77],  $p=0.008$ ) and all-cause mortality (0.34 [0.17–0.71],  $p=0.004$ ) for surgery relative to angioplasty in the period beyond 2 years from randomisation. There was no evidence of differential effectiveness of the interventions from the treatment by covariate interactions for either endpoint, overall or in any of the time periods. The covariates with the strongest independent effect on survival to the endpoints were the clinical stratification group, diabetes, creatinine concentration, and age.

At baseline, the two treatment groups were balanced in terms of HRQL. Patients in both treatment groups reported improved EQ5D and SF36 physical component summary scores by 3 months that were largely sustained during follow-up. However, little further improvement was seen beyond 3 months (table 4). We also recorded improvement over an extended period in the SF36 mental component summary score. Although there is weak evidence suggesting that HRQL may be somewhat better in the surgery group, there are no significant differences in HRQL between the two treatment groups. This finding is consistent across the three HRQL scores.

Table 5 compares the use of hospital resources on an intention-to-treat basis during the first 12 months from randomisation. Inpatient hospital costs per day were estimated at UK£421 for vascular surgical ward days, £591 for high-dependency unit days, and £1526 for intensive-therapy unit days. The average procedure costs were estimated as £3104 for surgery and £1159 for angioplasty.<sup>49</sup> Inpatient costs per day and procedure costs were reported on a price base of the financial year 2003–04. We recorded no difference between the two strategies with respect to the number of hospital admissions. However, patients assigned to receive surgery spent significantly longer in hospital and needed significantly more care in the high-dependency unit and intensive-therapy unit for the first 12 months than did those allocated angioplasty. Thus, 53 (23%) of patients given the surgery-first strategy needed high-dependency unit care and nine (4%) needed intensive-therapy unit care during the first 12 months of follow-up compared

	Number of events		Hazard ratio (95% CI) of surgery relative to angioplasty	
	Angioplasty (n=224)	Surgery (n=228)	Unadjusted	Adjusted*
<b>Amputation-free survival</b>				
Entire follow-up	106	98	0.89 (0.68–1.17)	0.88 (0.66–1.16)
Up to 6 months	46	50	1.07 (0.72–1.6)	1.04 (0.69–1.56)
After 6 months	60	48	0.75 (0.51–1.1)	0.73 (0.49–1.07)
After 2 years†	28	16	0.44 (0.22–0.88)	0.37 (0.17–0.77)
<b>All-cause mortality</b>				
Entire follow-up	87	79	0.90 (0.66–1.22)	0.95 (0.69–1.29)
Up to 6 months	26	31	1.20 (0.71–2.02)	1.27 (0.75–2.15)
After 6 months	61	48	0.78 (0.53–1.13)	0.81 (0.55–1.19)
After 2 years†	27	11	0.38 (0.19–0.77)	0.34 (0.17–0.71)

\*Adjusted for age, sex, clinical stratification group, body-mass index, current or ex-smoker status, creatinine concentration, diabetes, and statin use at baseline. †Post-hoc analysis done after examination of survival curves.

**Table 3: Comparison of hazard of amputation-free survival and all-cause mortality**

	Angioplasty (n=228)	Surgery (n=224)	Crude difference (mean [SE])	Adjusted difference for baseline score (mean [SE], number of patients)	p
<b>EQ5D weighted index score</b>					
Baseline	0.26 (0.32, 215)	0.29 (0.34, 206)	0.03 (0.03)	1	..
0–3 months	0.53 (0.31, 164)	0.57 (0.28, 152)	0.04 (0.03)	0.01 (0.03, 305)	0.87
3–6 months	0.52 (0.34, 144)	0.56 (0.31, 131)	0.05 (0.04)	0.04 (0.04, 267)	0.35
6–12 months	0.55 (0.31, 133)	0.62 (0.29, 119)	0.06 (0.04)	0.05 (0.04, 244)	0.19
<b>SF36 physical component summary</b>					
Baseline	17.50 (7.97, 213)	17.80 (9.06, 207)	0.30 (0.83)	1	..
0–3 months	23.80 (11.88, 163)	24.37 (12.45, 152)	0.57 (1.37)	-0.41 (1.25, 304)	0.74
3–6 months	24.62 (11.58, 144)	24.88 (13.51, 131)	0.26 (1.51)	-0.47 (1.35, 267)	0.73
6–12 months	24.58 (11.70, 133)	26.13 (13.54, 119)	1.56 (1.59)	0.08 (1.57, 245)	0.96
<b>SF36 mental component summary</b>					
Baseline	43.47 (11.64, 213)	45.17 (11.96, 207)	1.69 (1.15)	1	..
0–3 months	47.69 (11.28, 163)	48.68 (11.13, 152)	0.99 (1.26)	0.12 (1.22, 304)	0.92
3–6 months	46.67 (12.19, 144)	48.60 (10.75, 131)	1.93 (1.39)	1.72 (1.38, 267)	0.21
6–12 months	48.26 (11.76, 133)	50.16 (10.60, 119)	1.90 (1.42)	1.67 (1.33, 245)	0.21

Data are mean score (SD, number of patients) unless stated otherwise. Higher scores indicate better HRQL.

**Table 4: Comparison of HRQL by intention-to-treat analysis at different time points from randomisation**

with one (0.5%) and 16 (7%) of patients given the angioplasty-first strategy.

The mean cost of inpatient hospital treatment during the first 12 months of follow-up in patients assigned to a surgery-first strategy was estimated as £23 322 (£20 096 hospital stay, £3225 procedure costs), which is about a third higher than the £17 419 (£15 381, £2039) for patients assigned an angioplasty-first strategy.

## Discussion

As a multicentre, randomised controlled trial, BASIL compares the outcome of a bypass-surgery-first strategy with a balloon-angioplasty-first strategy in patients presenting with severe limb ischaemia due to infra-inguinal disease. We found that in the medium term, the outcomes after these two strategies are broadly similar with respect to amputation-free survival, all-cause mortality, and HRQL. However, if the different patient outcomes are analysed in more detail and over different time periods after their first intervention, the relative advantages and disadvantages of each strategy become apparent.

In the short term, a surgery-first strategy was associated with a significantly higher rate of morbidity, significantly greater length of hospital stay, and greater use of the high-dependency unit and intensive-therapy unit than that of an angioplasty-first strategy. Therefore, hospital costs of surgery for the first 12 months after randomisation were about a third higher than those of angioplasty. We recorded a high occurrence of cardiovascular, infective, and wound complications after surgery, and a small but clinically significant re-intervention rate for graft revision, thrombectomy, and evacuation of haematoma. However, the 30-day mortality after surgery, which was not significantly higher than that seen after angioplasty, was low considering the severity of the disease and comorbidity shown by this cohort of patients. The 30-day technical

	Surgery (n=228)		Angioplasty (n=224)		p*
	Mean (SD)	Range	Mean (SD)	Range	
Number of admissions to hospital	2.14 (1.30)	(1–8)	2.06 (1.50)	(0–10)	0.286
Total days spent in hospital	46.14 (53.87)	(0–365)	36.35 (51.39)	(0–334)	<0.0001
Days spent in intensive therapy unit	0.13 (0.94)	(0–12)	0.04 (0.60)	(0–9)	0.012
Days spent in high dependency unit	0.65 (1.60)	(0–11)	0.18 (1.17)	(0–16)	<0.0001
Number of surgical procedures	0.95 (0.50)	(0–4)	0.26 (0.52)	(0–3)	..
Number of angioplasty procedures	0.25 (0.54)	(0–3)	1.05 (0.36)	(0–3)	..

\*Wilcoxon two-sample test.

**Table 5: Comparison of use of hospital resources by intention to treat during first 12 months from randomisation**

failure rate was also low given the complexity of the surgery.

In the long term, after 2 years, surgery seemed to be associated with a significantly reduced risk of future amputation, death, or both—ie, if a patient was alive with their leg intact at 2 years after randomisation, they seemed to be more likely to remain alive in the future with their leg intact if they had been assigned to receive surgery first than angioplasty first. Although this result is highly significant, we should not overinterpret this finding since it is the result of a post-hoc analysis done after the surgical curves had been viewed, furthermore the numbers of endpoints after 2 years were small. However, this finding raises the intriguing possibility that, despite the increased short-term morbidity, patients could enjoy a more durable benefit from a surgery-first strategy than an angioplasty-first strategy.

We recorded a higher immediate failure and 12-month re-intervention rate in angioplasty than in surgery; however, morbidity associated with angioplasty was low, the hospital stay was short (thus the costs were lower), and there was no suggestion that a clinically failed angioplasty prejudiced the results of any subsequent surgery intervention that had been deemed necessary and appropriate. Unfortunately, a sizeable minority of

patients in both groups underwent repeated procedures only to eventually die or lose their leg (or both) within the first 12 months, which suggests that some patients might have been better served by primary amputation. Not surprisingly, the data indicate that the trial patients had a very low HRQL before treatment. We saw no significant difference in HRQL between the two strategies, which suggests that the patients' overwhelming concern was to have their pain relieved and amputation avoided, and how that was achieved was of much less importance to them in terms of HRQL.<sup>50</sup> There were short-term improvements in perceptions of physical and mental wellbeing but neither treatment led to continuing improvement in HRQL beyond the first few months. This finding could have been because patients with severe limb ischaemia are generally elderly and socially disadvantaged with multiple comorbidities.

The hospital costs over the first year were higher for surgery than for angioplasty. Although the procedural cost of the surgery was greater than that of angioplasty, the main difference was related to the length of hospital stay and, in particular, the much greater need for patients undergoing surgery to be cared for within a high-dependency-unit or intensive-therapy-unit environment. We did not attempt to quantify the use and associated costs of health and social services outside the hospitals. However, this proportion of cost would probably represent a large additional financial burden for certain patients, especially for those who ultimately need amputation.

As stated earlier, there was no evidence base before this trial. Previous studies<sup>6,20-24</sup> comparing the clinical effectiveness and cost-effectiveness of the two strategies for various degrees of lower limb ischaemia have had specific problems<sup>16</sup> such as a lack of controls; small patient numbers; poorly defined patients and interventions; the inclusion, comparison, and combined analysis of patients with intermittent claudication and severe limb ischaemia as well as with aorto-iliac and infra-inguinal disease; retrospective analysis; and short or incomplete follow-up (or both).<sup>18-21,25-32</sup>

Although not the main goal of the trial, it is worth noting that few study patients were on antiplatelet drug treatment and statin therapy and that many patients were current smokers on entry to the trial. The reasons for these characteristics are unclear and probably multifactorial. However, our results have also been seen in other studies of similar groups of patients.<sup>31</sup> Clear evidence shows that so-called best medical therapy (consisting of antiplatelet drugs, smoking cessation, and lipid-lowering therapy) can retard the development and progression of lower limb arterial disease. Best medical therapy is also associated with a large reduction in the risk of future cardiovascular events, including the need for limb-salvage intervention and amputation.<sup>3</sup> How many of the BASIL trial patients, had they been receiving best medical treatment, would have avoided

severe limb ischaemia and its consequences? An aggressive implementation of best medical treatment might have also improved the results of the trial interventions. Improvement of the medical management of patients with and at risk of developing severe limb ischaemia would seem to be an urgent priority in primary and secondary care.

The BASIL trial clearly indicates that, almost irrespective of what treatment is received, many patients with severe limb ischaemia have an extremely poor prognosis. Furthermore, our audit shows that up to half the patients presenting with severe limb ischaemia to major UK vascular units and undergoing diagnostic imaging are regarded as unsuitable or unfit for any form of revascularisation. Furthermore, an additional group of patients with severe limb ischaemia are not offered diagnostic imaging because their disease is too advanced or their medical condition is too poor. Thus, patients who undergo revascularisation for severe limb ischaemia, either by surgery or angioplasty, seem to represent the tip of an iceberg, the true dimensions of which remain incompletely defined. This result means that any randomised trial of interventions for severe limb ischaemia, including BASIL, will be restricted in its generalisability to the entire population of patients with the disorder, many of whom are actually treated conservatively or by primary amputation. However, the BASIL audit indicated that about a third of patients with severe limb ischaemia who undergo diagnostic imaging and are regarded as suitable for revascularisation, fell into the trial's grey area of equipoise; and more than two-thirds of these were randomised. Thus, the results of the BASIL trial are applicable and generalisable to very large numbers of patients presenting to vascular units with severe limb ischaemia and undergoing attempted revascularisation worldwide.

In summary, severe limb ischaemia imposes a very high human cost as well as a major economic burden on health and social care, not only in developed countries, but also increasingly in developing countries. We hope that the BASIL trial data will help vascular surgeons and radiologists advise, and obtain fully informed consent from, their patients in the knowledge that the decision-making process is based on level 1 evidence regarding the relative risks and benefits of strategies of bypass surgery first and balloon angioplasty first. The medium-term results of the BASIL trial indicate that patients presenting with severe limb ischaemia due to infra-inguinal atherosclerosis and who seem technically suitable for both treatments can reasonably be treated with either method in the first instance, depending on individual characteristics and local expertise. However, notwithstanding the high failure and re-intervention rate associated with angioplasty, patients who are expected to live for less than 1-2 years and have significant comorbidity should probably, when possible, be offered angioplasty first. Thus, even if the procedure fails, the



patient may not be disadvantaged in the short term and can go on to have surgery if regarded as appropriate. Angioplasty also seems to be a much less expensive option than surgery, at least in the short term. By contrast, in patients expected to live more than 2 years and who are relatively fit, the apparent improved durability and reduced re-intervention rate of surgery could outweigh the short-term considerations of increased morbidity and cost. Long-term follow-up and a detailed analysis of the BASIL trial dataset will probably allow these provisional recommendations to be refined in the future.

#### BASIL trial participants and contributors

**HTA grant applicants**—A W Bradbury (lead applicant), C V Ruckley, F G R Fowkes, J F Forbes, I Gillespie.

**Contributions of the writing committee**—D J Adam, J D Beard, and T Cleveland participated data analysis and writing of the paper. J Bell was the BASIL trial coordinator and participated in trial management, data collection, data analysis, and writing of the paper. A W Bradbury, was the principal investigator and participated in all aspects of trial design, grant application, delivery, analysis of the trial, and writing of the paper. J F Forbes was a grant co-applicant; participated in the trial design, data analysis, and writing of the paper; and had special responsibility for HRQL and health economics. F G R Fowkes, I Gillespie, and C V Ruckley were grant co-applicants and participated in the trial design, data analysis, and writing of the paper. G Raab was the trial statistician; and participated in design of the statistical plan, performance of the statistical analysis, and writing of the paper with special responsibility of the statistical sections and presentation of data. H Storkey participated in the performance of the statistical analysis and writing of the paper.

**Data management and statistical analysis**—J Bell (trial manager), G Raab, H Storkey.

**Data monitoring committee**—G D O Lowe (chairman), R M Greenhalgh, A Nicholson (R J Prescott and A Lee, as independent statisticians, prepared the data for the committee).

**Trial steering committee**—A W Bradbury (chairman), R Ashleigh, M Bain, J D Beard, J Brittenden, J F Forbes, F G R Fowkes, P Gaines, I Gillespie, S Girling, K McBride, J Moss, G Raab, C V Ruckley, G Stansby, G Welch, A Wilmink, D J Adam.

**Angiogram assessment and scoring**—K McBride, R Ashleigh.

**Research nurses**—G Bate, J Blundell, M Burrows, J Coleman, M Cullen, C Devine, L Holmes, G Horne, B Hughes, J Innes, M Ireland, C Judge, P Morris-Vincent, H Purdie, M Roseborough, J Simpson, R Stuart, T Uppal, B Walsh, B Watson, V Wealeans, L Wilson, S Zito.

**BASIL trial participants: consultant vascular surgeons and interventional radiologists, participating UK centres (number of patients entered into the trial); asterisk denotes centres taking part in the BASIL audit)**

P Bachoo, J Brittenden, G Cooper, S Cross, J Engeset, J Hussey, E Macauley, P Thorpe, \*Aberdeen Royal Infirmary, Aberdeen (58); G Stewart, K Osbourne, Ayr Hospital, Ayr (1); M Moss, P Nicholl, S Silverman, J Wingate, City Hospital, Birmingham (9); D Adam, B Balasubramanian, A Bradbury, P Crowe, J Ferrando, M Gannon, M Henderson, K Makhdoomi, D Mosquera, T Wilmink, \*Heart of England NHS Foundation Trust, Birmingham (33); T Buckenham, R Chalmers, R Dawson, S Fraser, I Gillespie, S Ingram, A Jenkins, J Murie, Z Raza, Edinburgh Royal Infirmary, Edinburgh (27); N Jones, D Lambert, T Lees, R Owen, J Rose, G Stansby, M Wyatt, \*Freeman Hospital, Newcastle (21); D Byrne, R Edwards, A MacKay, J Moss, R Quin, P Rogers, Gartnavel Hospital, Glasgow (23); D Gilmour, P Leiberman, D McCarter, A Reid, Glasgow Royal Infirmary, Glasgow (1); S Dodds, M Cleesby, A Jewkes, B Jones, C Nelson, A Parnell, Good Hope Hospital, Sutton Coldfield, Birmingham (11); P Bell, A Bolia, Leicester Royal Infirmary, Leicester (1); N Chalmers, I Mohan, V Smyth, M Walker, Manchester Royal Infirmary, Manchester (6); M Collins, A Garnham, G Mackie, New Cross Hospital, Wolverhampton (9); P Stonebridge, J Houston, Ninewells Hospital, Dundee (1); M Armon, J Clarke, J Cockburn, J Colin, S Girling, S Scott-Barrett, P Wilson, Y Wilson, \*Norfolk & Norwich Hospital, Norwich (60); J Beard, T Cleveland, P Chan, P Gaines, R Lonsdale, J Michaels, A Nassif, R Niar, J Rochester,

S Thomas, R Wood (deceased), \*Northern General Hospital, Sheffield (64); A Ashour, V Bhattachary, A Nudawi, G Timmons, Queen Elizabeth Hospital, Gateshead (2); A Howd, M Fleet, H Ireland, K McBride, A Milne, A Turner, Queen Margaret Hospital, Dunfermline (21); G Ferguson, M Onwudike, R Razzaq, J Tuck, Royal Bolton Infirmary, Bolton (5); D Baker, G Hamilton, F Hyint, A Platts, J Tibballs, A Watkinson, Royal Free Hospital, London (3); K Choji, R Grimley (deceased), A Jayatunga, R Patel, J Renny, S Shiralkar, A Wilinski, Russells Hall Hospital, Dudley (20); M Alner, M Duddy, A Edwards, M Simms, S Smith, R Vohra, Selly Oak Hospital, Birmingham (11); G MacBain, R Johnstone, G Urquhart, G Welch, Southern General Hospital, Glasgow (10); D Durrans, B Gwynn, C Willard, Staffordshire General Hospital, Stafford (2); M Thompson, R Morgan, St Georges Hospital, London (3); J Patel, J Scott, I Spark, St James Hospital, Leeds (2); K Allen, A Khan, J Holland, Walsall Manor Hospital, Walsall (4); R Ashleigh, S Butterfield, R England, C McCollum, A Nasim, M Welch, \*Wythenshawe Hospital, Manchester (44).

#### Conflict of interest statement

The members of the writing committee declare that they have no conflict of interest.

#### Acknowledgments

The BASIL trial was funded by the UK National Health Service (NHS) Research and Development Health Technology Assessment (HTA) programme. The views and opinions expressed here are not necessarily those of the UK NHS or HTA. The BASIL trial was made possible by the enthusiasm and commitment of the trial centres and we thank all the health-care personnel in those centres for their support of the study.

#### References

- 1 TASC. Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). Section D: chronic critical limb ischaemia. *Eur J Vasc Endovasc Surg* 2000; **19** (suppl A): S144–243.
- 2 Cavanagh PR, Lipsky BA, Bradbury AW, Botek G. Treatment for diabetic foot ulcers. *Lancet* 2005; **366**: 1725–35.
- 3 Burns P, Gough S, Bradbury AW. Management of peripheral arterial disease in primary care. *BMJ* 2003; **326**: 584–88.
- 4 Alber M, Romiti M, Brochado-Neto FC, Pereira CAB. Meta-analysis of alternate autogenous vein bypass grafts to infrapopliteal arteries. *J Vasc Surg* 2005; **42**: 449–55.
- 5 Wolffe KD, Bruijnen H, Loeprucht H, et al. Graft patency and clinical outcome of femorodistal arterial reconstruction in diabetic and non-diabetic patients: results of a multi-centre comparative analysis. *Eur J Vasc Endovasc Surg* 2003; **25**: 229–34.
- 6 van der Zaag ES, Legemate DA, Prins MH, Reekers JA, Jacobs MJ. Angioplasty or bypass for superficial femoral artery disease? A randomised controlled trial. *Eur J Vasc Endovasc Surg* 2004; **28**: 132–37.
- 7 Hobbs SD, Yapanis M, Burns PJ, Wilmink AB, Bradbury AW, Adam DJ. Peri-operative myocardial injury in patients undergoing surgery for critical limb ischaemia. *Eur J Vasc Endovasc Surg* 2005; **29**: 301–04.
- 8 Giswold ME, Landry GJ, Sexton GJ, et al. Modifiable patient factors are associated with reverse vein graft occlusion in the era of duplex scan surveillance. *J Vasc Surg* 2003; **37**: 47–53.
- 9 Nguyen LL, Conte MS, Menard MT, et al. Infringuinal vein bypass graft revision: factors affecting long-term outcome. *J Vasc Surg* 2004; **40**: 916–23.
- 10 Ishii Y, Gossage JA, Dourado R, Sabharwal T, Burnand KG. Minimum internal diameter of the greater saphenous vein is an important determinant of successful femorodistal bypass grafting that is independent of the quality of the runoff. *Vascular* 2004; **12**: 225–32.
- 11 Papavassiliou VG, Walker SR, Bolia A, Fishwick G, London N. Techniques for the endovascular management of complications following lower limb percutaneous transluminal angioplasty. *Eur J Vasc Endovasc Surg* 2003; **25**: 125–30.
- 12 Lipsitz EC, Ohki T, Veith FJ, et al. Fate of collateral vessels following subintimal angioplasty. *J Endovasc Ther* 2004; **11**: 269–73.
- 13 Lipsitz EC, Veith FJ, Ohki T. The value of subintimal angioplasty in the management of critical lower extremity ischemia: failure is not always associated with a rethreatened limb. *J Cardiovasc Surg* 2004; **45**: 231–37.

- 14 Bates MC, Aburahma AF. An update on endovascular therapy of the lower extremities. *J Endovasc Ther* 2004; **11** (suppl 2): I1107–27.
- 15 Baird RN, Bradley MD, Murphy KP. Tibioperoneal angioplasty and bypass. *Acta Chirurg Belgica* 2003; **103**: 383–87.
- 16 Bradbury AW. Angioplasty is the first line treatment for critical limb ischaemia: the case against. *Vascular and endovascular controversies*. London: BIBA Publishing, WB Saunders, 2003: 295–307.
- 17 Loftus IM, Hayes PD, Bell PR. Subintimal angioplasty in lower limb ischaemia. *J Cardiovasc Surg* 2004; **45**: 217–29.
- 18 Salas CA, Adam DJ, Papavassiliou VG, London NJ. Percutaneous transluminal angioplasty for critical limb ischaemia in octogenarians and nonagenarians. *Eur J Vasc Endovasc Surg* 2004; **28**: 142–45.
- 19 Treiman GS. Subintimal angioplasty for infrainguinal occlusive disease. *Surg Clin N Am* 2004; **84**: 1365–80.
- 20 Wolf GL, Wilson SE, Cross AP. Percutaneous transluminal angioplasty versus operation for peripheral arteriosclerosis. *J Vasc Surg* 1989; **9**: 1–9.
- 21 Holm J, Arfridsson B. Chronic lower limb ischaemia. A prospective randomised controlled trial comparing the 1-year results of vascular surgery and percutaneous transluminal angioplasty (PTA). *Eur J Vasc Surg* 1991; **5**: 517–22.
- 22 Nasr MK, McCarthy RJ, Hardman J, Chalmers A, Horrocks M. The increasing role of percutaneous transluminal angioplasty in the primary management of critical limb ischaemia. *Eur J Vasc Endovasc Surg* 2002; **23**: 398–403.
- 23 Roddy SP, Darling RC 3rd, Maharaj D, et al. Gender-related differences in outcome: an analysis of 5880 infrainguinal arterial reconstructions. *J Vasc Surg* 2003; **37**: 399–402.
- 24 Al-Omran M, Tu JV, Johnston KW, Mamdani MM, Kucey DS. Outcome of revascularization procedures for peripheral arterial occlusive disease in Ontario between 1991 and 1998: a population-based study. *J Vasc Surg* 2003; **38**: 279–88.
- 25 Sakethkoo RR, Razavi MK, Padidar A, Kee ST, Sze DY, Dake MD. Percutaneous bypass: subintimal recanalization of peripheral occlusive disease with IVUS guided luminal re-entry. *Tech Vasc Intervent Radiol* 2004; **7**: 23–27.
- 26 Desgranges P, Boufi M, Lapeyre M, et al. Subintimal angioplasty: feasible and durable. *Eur J Vasc Endovasc Surg* 2004; **28**: 138–41.
- 27 Clair DG, Dayal R, Faries PL, et al. Tibial angioplasty as an alternative strategy in patients with limb-threatening ischemia. *Ann Vasc Surg* 2005; **19**: 63–68.
- 28 Atar E, Siegel Y, Avrahami R, Bartal G, Bachar GN, Belenky A. Balloon angioplasty of popliteal and crural arteries in elderly with critical chronic limb ischemia. *Eur J Radiol* 2005; **53**: 287–92.
- 29 Surowiec SM, Davies MG, Eberly SW, et al. Percutaneous angioplasty and stenting of the superficial femoral artery. *J Vasc Surg* 41: 269–78.
- 30 Trocciola SM, Chaer R, Dayal R, et al. Comparison of results in endovascular interventions for infrainguinal lesions: claudication versus critical limb ischemia. *Am Surg* 2005; **71**: 474–80.
- 31 Tefera G, Hoch J, Turnipseed WD. Limb-salvage angioplasty in vascular surgery practice. *J Vasc Surg* 2005; **41**: 988–93.
- 32 Tartari S, Zattoni L, Rolma G, Sacco A. Subintimal angioplasty of infrapopliteal artery occlusions in the treatment of critical limb ischaemia. Short-term results. *Radiologia Medica* 2004; **108**: 265–74.
- 33 Leng GC, Davis M, Baker D. Bypass surgery for chronic lower limb ischaemia. *Cochrane Database Syst Rev* 2000; **3**: CD002000.
- 34 Jackson MJ, Wolfe JH. Are infra-inguinal angioplasty and surgery comparable? *Acta Chirurgica Belgica* 2001; **101**: 6–10.
- 35 Bradbury AW, Ruckley CV. Angioplasty for lower limb ischaemia: time for randomised controlled trials. *Lancet* 1996; **347**: 277–78.
- 36 Bradbury AW, Bell J, Lee AJ, et al. Bypass or angioplasty for severe limb ischaemia? A delphi consensus study. *Eur J Vasc Endovasc Surg* 2002; **24**: 411–16.
- 37 Schermerhorn ML, Cronenwett JL, Baldwin JC. Open surgical repair versus endovascular therapy for chronic lower-extremity occlusive disease. *Ann Rev Med* 2003; **54**: 269–83.
- 38 Bradbury A, Wilmink T, Lee AJ, et al. Bypass versus angioplasty to treat severe limb ischemia: factors that affect treatment preferences of UK surgeons and interventional radiologists. *J Vasc Surg* 2004; **39**: 1026–32.
- 39 Tsetis D, Belli AM. The role of infrapopliteal angioplasty. *Br J Radiol* 2004; **77**: 1007–15.
- 40 Bell J, Papp L, Bradbury AW. Bypass or angioplasty for severe ischaemia of the leg: the BASIL trial In: Greenhalgh RM, Powell JT, Mitchell AW, eds. *Vascular and endovascular opportunities*. London: WB Saunders, 2000: 485–94.
- 41 Wolfe JHN, Wyatt MG. Critical and sub-critical limb ischaemia. *Eur J Vasc Endovasc Surg* 1997; **13**: 578–82.
- 42 Caruana MF, Bradbury AW, Adam DJ. The validity, reliability, reproducibility and extended utility of ankle to brachial pressure index in current vascular surgical practice. *Eur J Vasc Endovasc Surg* 2005; **29**: 443–51.
- 43 EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. *Health Policy* 1990; **16**: 199–208.
- 44 Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): conceptual framework and item selection. *Med Care* 1992; **30**: 473–83.
- 45 Dolan P. Modeling valuations for EuroQol health states. *Med Care* 1997; **35**: 1095–108.
- 46 Ware JE, Kosinski M, Dewey JE. *How to score version two of the SF-36 health survey*. Lincoln, RI, USA: Quality Metric, 2000.
- 47 Abadie A, Drukker D, Herr JL, Imbens GW. Implementing matching estimators for average treatment effects in Stata. *Stat J* 2004; **4**: 290–311.
- 48 NHS National Services Scotland. *Scottish health service costs, year ended 31st March, 2004*. Edinburgh: Information Services Division, NHS National Services Scotland; 2004.
- 49 Michaels J, Brazier J, Palfreyman S, Shackley P, Slack R. Cost and outcome implications of the organisation of vascular services. *Health Technol Assess* 2000; **4**: no 11.
- 50 Hernandez-Osma E, Cairols MA, Marti X, Barjau E, Riera S. Impact of treatment on the quality of life in patients with critical limb ischaemia. *Eur J Vasc Endovasc Surg* 2002; **23**: 491–94.
- 51 Conte MS, Bandyk DF, Clowes AW, Moneta GL, Namini H, Seely L. Risk factors, medical therapies and peri-operative events in limb salvage surgery: observations from the PREVENT III multicentre trial. *J Vasc Surg* 2005; **42**: 456–65.